in this issue
Regions :: Western Europe :: Netherlands
DSM reports lower sales, earnings on negative currency effects, weakness in caprolactam
8:14 AM MDT | August 5, 2014 | Natasha Alperowicz
DSM today reported second-quarter net profit from continuing operations before exceptional items of €110 million ($147.6 million), 20% down on the year-earlier quarter. Revenues from continuing operations were flat, €2.29 billion, and Ebitda was 12% lower, €293 million. The nutrition segment's revenues dropped 3%, to €1.07 billion, and Ebitda was 11% down, at €222 million. The performance materials business recorded sales of €702 million, 1% down on the second quarter of 2013, and a 10% rise in Ebitda, to €88 million. Polymer...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee